Cargando…

One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA

BACKGROUND: Cachexia is a condition characterized as a loss in body mass or metabolic dysfunction and is associated with several prevalent chronic health conditions including many cancers, COPD, HIV, and kidney disease, with between 10 and 50% of patients with these conditions having cachexia. Curre...

Descripción completa

Detalles Bibliográficos
Autores principales: Arthur, Susan Tsivitse, Noone, Joshua M, Van Doren, Bryce A, Roy, Debosoree, Blanchette, Christopher M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Just Medical Media Limited 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130358/
https://www.ncbi.nlm.nih.gov/pubmed/25126097
http://dx.doi.org/10.7573/dic.212265
_version_ 1782330318701723648
author Arthur, Susan Tsivitse
Noone, Joshua M
Van Doren, Bryce A
Roy, Debosoree
Blanchette, Christopher M
author_facet Arthur, Susan Tsivitse
Noone, Joshua M
Van Doren, Bryce A
Roy, Debosoree
Blanchette, Christopher M
author_sort Arthur, Susan Tsivitse
collection PubMed
description BACKGROUND: Cachexia is a condition characterized as a loss in body mass or metabolic dysfunction and is associated with several prevalent chronic health conditions including many cancers, COPD, HIV, and kidney disease, with between 10 and 50% of patients with these conditions having cachexia. Currently there is little research into cachexia and our objective is to characterize cachexia patients, their healthcare utilization, and associated hospitalization costs. Given the increasing prevalence of chronic diseases, it is important to better understand cachexia so that the condition can be better diagnosed and managed. METHODS: We utilized one year (2009) of the Nationwide Inpatient Sample (NIS). The NIS represents all inpatient stays at a random 20% sample of all hospitals within the United States. We grouped cachexia individuals by primary or secondary discharge diagnosis and then compared those with cachexia to all others in terms of length of stay (LOS) and total cost. Finally we looked into factors predicting increased LOS using a negative binomial model. RESULTS: We estimated US prevalence for cachexia-related inpatient admissions at 161,898 cases. Cachexia patients were older, with an average age of 67.95 versus 48.10 years in their non-cachexia peers. Hospitalizations associated with cachexia had an increased LOS compared to non-cachexia patients (6 versus 3 days), with average costs per stay $4641.30 greater. Differences were seen in loss of function (LOF) with cachexia patients, mostly in the major LOF category (52.60%), whereas non-cachexia patients were spread between minor, moderate, and major LOF (36.28%, 36.11%, and 21.26%, respectively). Significant positive predictors of increased LOS among cachexia patients included urban hospital (IRR=1.21, non-teaching urban; IRR=1.23, teaching urban), having either major (IRR=1.41) or extreme (IRR=2.64) LOF, and having a primary diagnosis of pneumonia (IRR=1.15). CONCLUSION: We have characterized cachexia and seen it associated with increased length of stay, increased cost, and more severe loss of function in patients compared to those without cachexia.
format Online
Article
Text
id pubmed-4130358
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Just Medical Media Limited
record_format MEDLINE/PubMed
spelling pubmed-41303582014-08-14 One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA Arthur, Susan Tsivitse Noone, Joshua M Van Doren, Bryce A Roy, Debosoree Blanchette, Christopher M Drugs Context Original Research BACKGROUND: Cachexia is a condition characterized as a loss in body mass or metabolic dysfunction and is associated with several prevalent chronic health conditions including many cancers, COPD, HIV, and kidney disease, with between 10 and 50% of patients with these conditions having cachexia. Currently there is little research into cachexia and our objective is to characterize cachexia patients, their healthcare utilization, and associated hospitalization costs. Given the increasing prevalence of chronic diseases, it is important to better understand cachexia so that the condition can be better diagnosed and managed. METHODS: We utilized one year (2009) of the Nationwide Inpatient Sample (NIS). The NIS represents all inpatient stays at a random 20% sample of all hospitals within the United States. We grouped cachexia individuals by primary or secondary discharge diagnosis and then compared those with cachexia to all others in terms of length of stay (LOS) and total cost. Finally we looked into factors predicting increased LOS using a negative binomial model. RESULTS: We estimated US prevalence for cachexia-related inpatient admissions at 161,898 cases. Cachexia patients were older, with an average age of 67.95 versus 48.10 years in their non-cachexia peers. Hospitalizations associated with cachexia had an increased LOS compared to non-cachexia patients (6 versus 3 days), with average costs per stay $4641.30 greater. Differences were seen in loss of function (LOF) with cachexia patients, mostly in the major LOF category (52.60%), whereas non-cachexia patients were spread between minor, moderate, and major LOF (36.28%, 36.11%, and 21.26%, respectively). Significant positive predictors of increased LOS among cachexia patients included urban hospital (IRR=1.21, non-teaching urban; IRR=1.23, teaching urban), having either major (IRR=1.41) or extreme (IRR=2.64) LOF, and having a primary diagnosis of pneumonia (IRR=1.15). CONCLUSION: We have characterized cachexia and seen it associated with increased length of stay, increased cost, and more severe loss of function in patients compared to those without cachexia. Just Medical Media Limited 2014-07-31 /pmc/articles/PMC4130358/ /pubmed/25126097 http://dx.doi.org/10.7573/dic.212265 Text en Copyright © 2014 Arthur ST, Noone JM, Van Doren BA, Roy D, Blanchette CM Distributed under the terms of the Creative Commons Attribution License Deed CC BY 3.0. which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No other uses without permission.
spellingShingle Original Research
Arthur, Susan Tsivitse
Noone, Joshua M
Van Doren, Bryce A
Roy, Debosoree
Blanchette, Christopher M
One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA
title One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA
title_full One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA
title_fullStr One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA
title_full_unstemmed One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA
title_short One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA
title_sort one-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the usa
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130358/
https://www.ncbi.nlm.nih.gov/pubmed/25126097
http://dx.doi.org/10.7573/dic.212265
work_keys_str_mv AT arthursusantsivitse oneyearprevalencecomorbiditiesandcostofcachexiarelatedinpatientadmissionsintheusa
AT noonejoshuam oneyearprevalencecomorbiditiesandcostofcachexiarelatedinpatientadmissionsintheusa
AT vandorenbrycea oneyearprevalencecomorbiditiesandcostofcachexiarelatedinpatientadmissionsintheusa
AT roydebosoree oneyearprevalencecomorbiditiesandcostofcachexiarelatedinpatientadmissionsintheusa
AT blanchettechristopherm oneyearprevalencecomorbiditiesandcostofcachexiarelatedinpatientadmissionsintheusa